Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

W, Tang; Z, Cao; M, Han; Z, Wang; J, Chen; W, Sun; Y, Wu; W, Xiao; S, Liu; E, Chen; W, Chen; X, Wang; J, Yang; J, Lin; Q, Zhao; Y, Yan; Z, Xie; D, Li; Y, Yang; L, Liu; J, Qu; G, Ning; G, Shi; Q, Xie

doi:10.1136/bmj.m1849

Public

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

Shared by NobleBlocks on May 14, 2020 • 12:00 AM UTC

Authors:

Tang W

Cao Z

Han M

Abstract

Objective To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).Design Multicentre, open label, randomised controlled trial.Setting 16 government designated covid-19 treatment centres in C...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!